These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37969380)

  • 1. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.
    Hao L; Dong J; Yu H; Chen J; Han X; Pan Y
    Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
    Ligorio F; Fucà G; Zattarin E; Lobefaro R; Zambelli L; Leporati R; Rea C; Mariani G; Bianchi GV; Capri G; de Braud F; Vernieri C
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients.
    Huszno J; Kolosza Z
    Oncol Lett; 2019 Dec; 18(6):6275-6283. PubMed ID: 31788105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
    Leng J; Wu F; Zhang L
    Front Oncol; 2022; 12():734948. PubMed ID: 35651788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
    Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
    Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
    Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
    Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
    Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
    BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
    Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
    Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy.
    D'Emic N; Engelman A; Molitoris J; Hanlon A; Sharma NK; Moeslein FM; Chuong MD
    J Gastrointest Oncol; 2016 Apr; 7(2):269-77. PubMed ID: 27034796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma.
    Liu S; Xu W; Shu H; Dai Y; Du Y; Liu Y; Huang L; Sun G
    Cancer Med; 2023 Dec; 12(24):21830-21848. PubMed ID: 38054365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population.
    Ramos-Esquivel A; Rodriguez-Porras L; Porras J
    Breast Dis; 2017; 37(1):1-6. PubMed ID: 28035906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with radical cystectomy for bladder cancer.
    Shi H; Wang K; Yuan J; Mao W; Wu Z; Liu Q; Xie J; Peng B
    Transl Cancer Res; 2020 Sep; 9(9):5255-5267. PubMed ID: 35117892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
    Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
    Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.